BHP Attracts AI-Focused Investors as Copper Demand Surges 
Intel Emerges as Key Contender in Apple’s Chip Manufacturing Strategy Shift 
Orsted Q1 EBITDA Beats Expectations Despite U.S. Impairments 
Strategy Hints at Bitcoin Sales to Cover Dividends After Massive Q1 Loss 
Palantir Reports Record Growth, Raises 2026 Revenue Outlook Above Expectations 
Maersk Q1 Earnings Beat Expectations as Iran Conflict Clouds Shipping Outlook 
Apple Explores Intel and Samsung Partnerships to Diversify Chip Supply Chain 
Volvo Car Sales Drop 10% in Early 2026 Despite Growth in Electric Vehicles 
Aker BP Q1 Profit Jumps on Higher Oil Prices and Asset Reversal 
Hua Hong Semiconductor Stock Surges to Multi-Year High Amid AI Boom 
China Banks Halt New Loans to Sanctioned Refineries Amid U.S.-Iran Oil Crackdown 
Pinterest Stock Surges After Strong Q1 2026 Earnings Beat Expectations 
Hugo Boss Beats Q1 Profit Expectations Despite Market Headwinds 
UOB Q1 Profit Meets Expectations as Loan Growth Offsets Lower Interest Rates 
Philips Reaffirms 2026 Outlook After Strong Q1 Sales and Margin Beat 
BMW Keeps 2026 Outlook Despite 25% Profit Drop Amid Tariff Pressure 
Agentic AI Boom to Drive Massive Growth in CPU Market, UBS Says 
CHARLESTON, S.C., May 01, 2018 -- Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX:AEZS) will announce its first quarter 2018 financial and operating results after market close on Monday, May 7, 2018. The Company will host a conference call to discuss these results on Tuesday, May 8, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13679691
- Toll: 201-689-8029, Confirmation #13679691
A replay will also be available on the Company’s website for a period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing arrangements, Macrilen™ (macimorelin), an orally available ghrelin agonist, to be used in the diagnosis of patients with adult growth hormone deficiency. Aeterna Zentaris has entered into a license and assignment agreement with a wholly-owned subsidiary of Strongbridge Biopharma plc to carry out development, manufacturing, registration and commercialization of Macrilen™ (macimorelin) in the United States and Canada. For more information, visit www.aezsinc.com.
Contact:
Aeterna Zentaris Inc.
James Clavijo
Chief Financial Officer
[email protected]
843-900-3201
